Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 5.68
- Piotroski Score 3.00
- Grade Buy
- Symbol (KURA)
- Company Kura Oncology, Inc.
- Price $10.04
- Changes Percentage (-36.87%)
- Change -$5.87
- Day Low $9.68
- Day High $12.24
- Year High $24.17
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $26.50
- High Stock Price Target $32.00
- Low Stock Price Target $19.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.17
- Trailing P/E Ratio -10.03
- Forward P/E Ratio -10.03
- P/E Growth -10.03
- Net Income $-152,631,000
Income Statement
Quarterly
Annual
Latest News of KURA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Kura Sushi USA Clears Key Benchmark, Hitting 80-Plus RS Rating
Learn how to find the best IPO stocks using a proprietary rating system that measures market leadership on a scale of 1 to 99. Stocks with an RS Rating above 80 tend to yield the biggest gains....
By Investor's Business Daily | 1 day ago -
Kura Oncology Shares Fall 14% on Plans for Cancer-Drug Collaboration
Kura Oncology's stock declined 14% in after-hours trading due to a collaboration deal with Kyowa Kirin for its leukemia treatment. The agreement includes significant upfront and milestone payments, wi...
By MarketWatch | 1 day ago -
Exploring SAKURA Internet And Two Other High Growth Tech Stocks In Japan
In the midst of Japan's stock market decline, investors are eyeing high-growth sectors like technology for opportunities. Companies like SAKURA Internet Inc. and Nissha Co., Ltd. are showing promise w...
By Yahoo! Finance | 3 weeks ago
